GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Indegene Ltd (NSE:INDGN) » Definitions » Notes Receivable

Indegene (NSE:INDGN) Notes Receivable : ₹0 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Indegene Notes Receivable?

Indegene's Notes Receivable for the quarter that ended in Mar. 2025 was ₹0 Mil.


Indegene Notes Receivable Historical Data

The historical data trend for Indegene's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indegene Notes Receivable Chart

Indegene Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Notes Receivable
- - - - -

Indegene Quarterly Data
Mar21 Mar22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Indegene Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Indegene Notes Receivable Related Terms

Thank you for viewing the detailed overview of Indegene's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Indegene Business Description

Traded in Other Exchanges
Address
Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.

Indegene Headlines

No Headlines